0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Avecho Biotechnology
Its shares trade on ASX under the ticker AVE.AX. It has been listed since 11 August 1993. In the fiscal year to 31 December 2025, it reported revenue of A$1.2m and a net loss of A$4.4m. At that date it held total assets of A$7.1m and shareholders' equity of A$1.6m.
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The principal activities of the Company are the development, production, sale and licensing of products incorporating its platform technology Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care, and animal health and nutrition industries. The firm's segments include Production and Personal Care, and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers delivery of drugs through gels, injectables and patches. The Human Health segment focuses on development of patches, including TPM/Oxymorphone and TPM/Oxycodone. The firm has various development programs under its animal health and nutrition. The firm has completed multiple studies assessing TPM as a feed additive in pigs and poultry.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Aug 1993
- Employees
- 29
- Website
- avecho.com.au ↗
Leadership
Pay as last reported
- Dr. Gregory CollierNon-Executive Chairman of the Board, since 2015A$100,000
- Dr. Paul GavinChief Executive OfficerA$256,823
- Dr. Roksan LibinakiChief Operating Officer, since 2020A$302,323
- Ms. Melanie LeydinCompany Secretary
- Ms. Katherine ConnellNon-Executive DirectorA$46,053
- Mr. Matthew McnamaraNon-Executive DirectorA$55,263
- Dr. Ross MurdochNon-Executive Independent Director, since 2015A$55,263
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 44
- Social
- 42
- Governance
- 36
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Avecho Biotechnology Ltd possesses several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with a deep understanding of the biotechnology industry. This expertise allows Avecho to make informed decisions and navigate complex regulatory processes.
- Secondly, Avecho boasts a robust portfolio of intellectual property rights, including patented technologies and proprietary formulations. These assets provide the company with a competitive edge and create barriers to entry for potential competitors.
- Furthermore, Avecho has established strategic partnerships with reputable research institutions and industry leaders. This collaboration enables the company to access cutting-edge research, resources, and expertise, enhancing its ability to innovate and develop high-quality products.
Weaknesses
- Despite its strengths, Avecho Biotechnology Ltd is not without weaknesses. One key weakness is its limited size and resource allocation. As a small company, Avecho may face challenges in terms of funding and scalability. This limitation may hinder its ability to compete with larger biotechnology firms that have greater financial capabilities.
- Another weakness is Avecho's dependency on a few key products. Although the company has a diverse product pipeline, the success or failure of a small number of products can significantly impact its financial performance. This concentration risk exposes Avecho to potential market volatility and regulatory uncertainties.
Opportunities
- Avecho Biotechnology Ltd can capitalize on various opportunities within the biotechnology industry. One opportunity lies in the increasing demand for innovative therapeutics and drug delivery systems. Avecho's expertise in formulation development positions it well to address this growing market need.
- Additionally, the global focus on personalized medicine and targeted therapies presents an opportunity for Avecho. The company can leverage its intellectual property and partnerships to develop customized treatments that cater to individual patients, leading to improved patient outcomes and market differentiation.
Threats
- Several threats exist in Avecho Biotechnology Ltd's operating environment. The biotechnology industry is highly regulated, and changes in regulations or the introduction of new legislation can impact Avecho's ability to develop and commercialize its products. Adapting to evolving regulatory requirements poses a constant challenge.
- Moreover, Avecho faces intense competition from both existing pharmaceutical companies and emerging biotech startups. This competition may result in pricing pressures, market share erosion, or the loss of key talent to rival firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.